Healthcare
Cannara Biotech Inc.(LOVFF)
Live Price
Offline$1.16
-1.03% today
1Y Change
+15.79%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $170.00M
- Revenue Growth
- +31.3%
- EPS Growth
- +120.1%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cannara Biotech Inc. (LOVFF) is a Healthcare stock with a market cap of $170.00M and listed on OTC. The stock last traded around $1.16 and up 15.8% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +31.3%, EPS growth of +120.1%, a dividend yield of 0.0%. What stands out right now is revenue +31.3%, EPS +120.1%, free cash flow +324.9% with operating margin 14.1% and ROIC 7.2%. Valuation is more restrained than many high-expectation growth names at P/E 13.8 and price/sales 1.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines LOVFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+31.3% vs +7.6% peer median
Operating Margin
Below sector median
+14.1% vs +19.4% peer median
P/E
Below sector median
13.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +31.3% and EPS at +120.1%, with operating margin around 14.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +0.8% | +1.6% | -3.8% |
2026 Apr 27, 2026 | โ | -2.3% | -3.0% | -6.1% |
2026 Jan 26, 2026 | โ | -4.7% | -10.3% | -2.9% |
Benchmark Edge
LOVFF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LOVFF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LOVFF Max Drawdown
-20.35%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LOVFF and SPY.
Company Overview
Cannara Biotech Inc.
Other OTC
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
- Leadership
- Zohar Krivorot
- IPO Date
- Jan 18, 2019
- Employees
- 461
- Street Address
- 333 Decarie Blvd.
- Mailing
- Saint-Laurent, QC, H4N 3M9
- Region
- Saint-Laurent, QC, CA
- Reporting Currency
- USD
- Investor Line
- 514-543-4200
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 13.8
- EV/EBITDA
- 7.0
- Price/Sales
- 1.5
- Price/Book
- 1.5
Growth
- Revenue
- +31.3%
- EPS
- +120.1%
- Free Cash Flow
- +324.9%
Profitability
- Gross Margin
- 38.6%
- Operating Margin
- 14.1%
- Net Margin
- 10.5%
- ROE
- 11.6%
- ROIC
- 7.2%
Balance Sheet
- Debt/Equity
- 0.31
- Current Ratio
- 2.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.